Amplify Transformational Data Sharing ETF vs Pfizer Inc — how do they compare? Amplify Transformational Data Sharing ETF trades at $61.14, while Pfizer Inc trades at $24.29 (market cap $138.21B). The key difference: Pfizer Inc pays a 7.09% dividend while Amplify Transformational Data Sharing ETF pays none, and Amplify Transformational Data Sharing ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| BLOK | PFE | |
|---|---|---|
52-Week High | $74.10 | $28.56 |
52-Week Low | $47.36 | $23.29 |
Market Cap | — | $138.21B |
Volume | — | 29,869,932 |
Sector | — | Health |
Enterprise Value | — | $188.87B |
Dividend Yield | — | 7.09% |
Signals from Pluang's Aura AI — not financial advice
BLOK trades at $60.81, down 2.95% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators remain neutral. Recent news highlights the fund's diversified blockchain economy exposure, including bitcoin miners and enterprise adopters. The company announced a $0.08 dividend scheduled for June 2026, providing income potential for shareholders.
Outlook remains cautious with technical indicators signaling bearish momentum. The fund's increased bitcoin exposure to approximately 40% introduces volatility risks, though diversification across AI infrastructure and payment processors offers some stability. Investment opportunity exists for long-term investors seeking blockchain economy exposure, but near-term performance depends heavily on crypto market direction and AI infrastructure growth.
Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.
The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.
Trailing returns across standard periods
Latest headlines on both assets
The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.
Read more on BLOK →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →